Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00457392
Status:
COMPLETED
Last Update Posted:
2013-10-29
First Post:
2007-04-04
Brief Title:
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Controlled Phase 3 Efficacy And Safety Study Of Sunitinib SU011248 In Patients With AdvancedMetastatic Non-Small Cell Lung Cancer Treated With Erlotinib
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advancedmetastatic lung cancer who have received previous treatment with a platinum-based regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SUN1087 | None | None | None |